Genomic Health, Janssen Partner to Advance Test Predicting Best Treatment for Low-Risk Prostate Cancer

Genomic Health, Janssen Partner to Advance Test Predicting Best Treatment for Low-Risk Prostate Cancer
Genomic Health announced has entered a multi-year agreement with Janssen Pharmaceuticals to evaluate its genomic expression test intended to aid in the treatment of recently diagnosed and low-risk prostate cancer patients. As part of the agreement, Genomic Health will test samples from Janssen studies to examine how well Oncotype DX Genomic Prostate Score (GPS) test results match clinical

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *